Gbenga Kazeem

Learn More
This open-label study compared docetaxel/gemcitabine vs. paclitaxel/gemcitabine and a weekly (W) vs. 3-weekly (3 W) schedule in metastatic breast cancer (MBC). Patients relapsed after adjuvant/neoadjuvant anthracycline-containing chemotherapy were randomized to: A) gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W; B) gemcitabine 1250 mg/m2 Day(More)
INTRODUCTION Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. METHODS NSCLC stage(More)
BACKGROUND ADVANCE (NCT01304836) was a phase 4, multicenter, prospectively randomized, open-label, 24-week study comparing the incidence of posttransplantation diabetes mellitus (PTDM) with 2 prolonged-release tacrolimus corticosteroid minimization regimens. METHODS All patients received prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and(More)
Lucia Del Mastro (lucia.delmastro@istge.it) Alessandra Fabi (fabi@ifo.it) Mauro Mansutti (mansutti.mauro@aoud.sanita.fvg.it) Michele De Laurentiis (delauren@unina.it) Antonio Durando (antonio.durando@libero.it) Domenico Franco Merlo (franco.merlo@istge.it) Paolo Bruzzi (paolo.bruzzi@istge.it) Ignazia La Torre (cinzialt@yahoo.com) Matteo Ceccarelli(More)
ADHERE was a randomized, open-label, Phase IV study comparing renal function at Week 52 postkidney transplant, in patients who received prolonged-release tacrolimus-based immunosuppressive regimens. On Days 0-27, patients received prolonged-release tacrolimus (initially 0.2 mg/kg/day), corticosteroids, and mycophenolate mofetil (MMF). Patients were(More)
  • 1